Metagenomi Therapeutics MGX

Metagenomi Therapeutics, Inc. is an in vivo genome editing company that was founded on the science of metagenomics to discover and develop curative genetic medicines for patients. The company has generated over 20,000 signature gene editing systems from its proprietary metagenomics database and uses machine learning to refine these tools. Its lead program MGX-001 employs a site specific liver directed gene insertion strategy to deliver durable Factor VIII expression for the treatment of hemophilia A from a single administration. Beyond hemophilia A, Metagenomi Therapeutics is advancing additional wholly owned candidates that leverage the MGX-001 large gene insertion system for other secreted protein deficiencies such as antithrombin III. The company also pursues partnered programs that focus on protein reduction via gene knockout in cardiometabolic indications through its collaboration with Ionis Pharmaceuticals. All programs aim to achieve curative therapeutics by correcting or modulating disease causing genes using proprietary nucleases and editing platforms. Metagenomi Therapeutics leverages its metagenomics derived nucleases including SMART systems and base editors to expand targeting range and improve precision beyond commonly used CRISPR Cas9 systems.

Metagenomi Therapeutics generates revenue primarily through collaboration agreements licensing fees milestone payments and potential royalties from pharmaceutical partners. In November 2022 the company received an upfront payment of $80 million from Ionis Pharmaceuticals for its Wave 1 drug discovery collaboration covering four cardiometabolic targets. Under the Ionis agreement Metagenomi Therapeutics is eligible to receive up to $29 million in development milestone payments up to $60 million in regulatory milestone payments and up to $250 million in sales based milestones for each licensed product. The company also stands to earn royalties ranging from a mid single digit to a low teens percentage on net sales of any commercialized products arising from the Ionis partnership. As of December 2025 Metagenomi Therapeutics has received $5.8 million in reimbursements for exploratory research expenses under the Ionis agreement with a total potential reimbursement of up to $10 million. In September 2025 the company entered into a non exclusive license with Acuitas Therapeutics for lipid nanoparticle technology requiring an upfront fee of $3 million and obligating Metagenomi Therapeutics to pay maintenance fees milestone payments and low to mid single digit royalties on net sales of products that incorporate the Acuitas LNP platform. Additional revenue may arise from future licensing or partnership arrangements for its proprietary gene editing systems including its SMART nucleases base editors CAST and RIGS technologies.

Metagenomi Therapeutics competes in the genome editing sector alongside companies such as Caribou Biosciences Editas Medicine CRISPR Therapeutics Intellia Therapeutics Sangamo Therapeutics Precision BioSciences Beam Therapeutics Verve Therapeutics Prime Medicine and Tessera Therapeutics. The company’s competitive advantage stems from its proprietary metagenomics derived nucleases which include ultra small SMART systems capable of AAV delivery and a broad repertoire of base editors that achieve high multiplex editing with high specificity. Metagenomi Therapeutics has demonstrated its ability to perform large gene insertion using its CAST technology and to execute programmable RNA and DNA mediated integration via its RIGS platforms. The firm’s intellectual property portfolio comprises 11 issued U S patents 46 pending U S non provisional applications 10 pending U S provisional applications 29 issued foreign patents 295 pending foreign applications and 11 PCT applications covering various nuclease types. This extensive estate provides a barrier to entry and supports long term protection of its therapeutic candidates. Additionally the company’s integration of machine learning with its metagenomics discovery engine enhances the identification of novel editing tools and improves the precision of its gene editing systems.

Metagenomi Therapeutics customer base consists primarily of pharmaceutical and biotechnology partners that collaborate on its drug discovery and development programs. The company’s current collaborators include Ionis Pharmaceuticals with whom it is advancing four cardiometabolic targets in Wave 1 of their partnership and Acuitas Therapeutics which provides lipid nanoparticle technology for its gene editing constructs. These collaborations provide upfront funding research reimbursement milestone payments and potential commercialization pathways for Metagenomi Therapeutics pipeline. While the company has previously worked with entities such as Affini T and Moderna those agreements have been terminated and are not part of its present revenue generating relationships. Ultimately Metagenomi Therapeutics aims to deliver curative therapies to patients suffering from genetic disorders but its near term customers are the partners that fund and support its research and development activities.